m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01915)
Name
PF-3644022
Synonyms
PF3644022; PF 3644022
    Click to Show/Hide
Status
Investigative
Structure
Formula
C21H18N4OS
InChI
1S/C21H18N4OS/c1-11-3-4-13(10-22-11)15-6-5-14-16(25-15)7-8-17-18(14)19-20(27-17)21(26)24-12(2)9-23-19/h3-8,10,12,23H,9H2,1-2H3,(H,24,26)/t12-/m1/s1
InChIKey
CMWRPDHVGMHLSZ-GFCCVEGCSA-N
PubChem CID
44631903
TTD Drug ID
D06QBJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
MAPK-activated protein kinase 2 (MAPKAPK2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for PF-3644022. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-3644022 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6832-5. doi: 10.1016/j.bmcl.2007.10.036. Epub 2007 Oct 17.